Teva Gets Mixed Rulings in Antitrust Cases Involving MS Drug

April 13, 2026, 11:09 PM UTC

Teva Pharmaceuticals Industries Ltd. dodged some claims and will continue to litigate others in multidistrict litigation brought by drug wholesalers and retailers, as well as a suit brought by a rival, alleging that the company harmed generic competition for the multiple sclerosis drug Copaxone.

Judge Julien Xavier Neals of the US District Court for the District of New Jersey on Monday adopted a special master’s report to deny Teva’s motion to dismiss claims in the MDL that it made illegally exclusive deals with pharmacy benefit managers to block generic Copaxone.

Special Master Faith S. Hochberg correctly concluded the plaintiffs “plausibly ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.